5 completed, 4 active not recruiting, 4 recruiting, 2 terminated. 3 Phase 3, 2 Not applicable, 2 Phase 1, 1 Early Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Not yet recruiting 1 |
| Not applicable | 2 | Completed 1, Recruiting 1 |
| Phase 1 | 2 | Completed 2 |
| Early Phase 1 | 1 | Recruiting 1 |
| Phase 4 | 1 | Active not recruiting 1 |
Follow diroximel fumarate: new trials by email Literature Review of diroximel fumarate trials Research Report on diroximel fumarate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS) Diroximel Fumarate, Dimethyl Fumarate, Fingolimod - Relapsing Forms of Multiple Sclerosis | Phase 3 | Not yet recruiting | Biogen | 185 | 2026-11-16 | 2026-03-19 |
| Investigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia Diroximel fumarate (DRF), Placebo - Schizophrenia Disorders | Not applicable | Recruiting | King's College London | 30 | 2025-01-10 | 2026-02-13 |
| Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease Vumerity, Placebo - Peripheral Artery Disease, Peripheral Vascular Diseases | Early Phase 1 | Recruiting | University of Nebraska | 20 | 2024-11-14 | 2026-06-24 |
| A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS) Diroximel Fumarate, Dimethyl Fumarate, Disease-Modifying Therapies (DMTs) - Multiple Sclerosis | Active not recruiting | Biogen | 10500 | 2024-06-08 | 2026-10-26 | |
| Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate) Diroximel Fumarate, Avonex, Tysabri - Multiple Sclerosis | Recruiting | Biogen | 908 | 2023-10-27 | 2026-08-11 | |
| Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Dimethyl Fumarate (Tecfidera) or Diroximel Fumarate (Vumerity) Vumerity, Tecfidera - Multiple Sclerosis (MS) Relapsing Remitting | Active not recruiting | University of Colorado, Denver | 11 | 2023-03-07 | 2026-08-11 | |
| A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis ofatumumab, glatiramer acetate, interferon β1 - Relapsing Multiple Sclerosis | Recruiting | Novartis Pharmaceuticals | 800 | 2022-05-10 | 2026-07-30 | |
| Exploring Diroximel Fumarate Real-world Experience in Canada and Israel Diroximel Fumarate - Relapsing Forms of MS | Terminated | Biogen | 64 | 2021-12-09 | 2023-05-10 | |
| A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Diroximel Fumarate (DRF) in Chinese and Caucasian Adult Healthy Participants Diroximel fumarate - Healthy Volunteers | Phase 1 | Completed | Biogen | 32 | 2021-12-03 | 2022-07-05 |
| A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS) Diroximel fumarate - Relapsing Forms of Multiple Sclerosis | Phase 3 | Completed | Biogen | 136 | 2021-11-18 | 2025-10-24 |
| A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies Diroximel Fumarate, Alemtuzumab, Fingolimod - Multiple Sclerosis | Active not recruiting | Biogen | 1178 | 2021-09-24 | 2026-10-15 | |
| Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS Ofatumumab, First line DMT - Multiple Sclerosis | Phase 3 | Completed | Novartis Pharmaceuticals | 185 | 2021-07-23 | 2026-03-03 |
| Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects Monomethyl Fumarate 190 Mg, Diroximel Fumarate 462 mg - Relapsing Remitting Multiple Sclerosis | Phase 1 | Completed | Banner Life Sciences LLC | 46 | 2021-05-14 | 2022-01-06 |
| Study of Diroximel Fumarate in the Real-World Setting Diroximel Fumarate - Relapsing Forms of MS | Terminated | Biogen | 75 | 2021-03-01 | 2023-05-26 | |
| Relationship Between Oral DMT Burden and Adherence in MS Cladribine, Dimethyl fumarate, Fingolimod - Multiple Sclerosis, Adherence, Medication | Unknown | Monash University | 323 | 2020-09-25 | 2022-08-31 | |
| Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS Early Highly Effective Therapies Group, Escalation Therapies Group - Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Active not recruiting | The Cleveland Clinic | 800 | 2019-01-03 | 2026-08-31 |
| Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod - Multiple Sclerosis, Relapsing-Remitting | Not applicable | Completed | Johns Hopkins University | 900 | 2018-05-02 | 2026-09-23 |
Multiple Sclerosis (7) · Multiple Sclerosis, Relapsing-Remitting (4) · Inflammation (1) · Medication Adherence (1) · Peripheral Arterial Disease (1) · Peripheral Arterial Occlusive Disease 1 (1) · Peripheral Vascular Diseases (1) · Psychotic Disorders (1) · Schizophrenia (1)
Biogen (8) · Novartis Pharmaceuticals (2) · Banner Life Sciences LLC (1) · Johns Hopkins University (1) · King's College London (1) · Monash University (1) · The Cleveland Clinic (1) · University of Colorado, Denver (1) · University of Nebraska (1)
United States (9) · Germany (3) · United Kingdom (3) · Australia (2) · Spain (2) · China (1) · France (1) · Hong Kong (1) · Ireland (1) · Israel (1) · Italy (1) · Japan (1) · New Zealand (1) · Switzerland (1)
Daniel Ontaneda, MD, MSc (1) · Ellen M. Mowry, MD, MCR (1) · Enrique Alvarez, MD/PhD (1) · Ernest Butler, PhD; MD (1) · Franck Rousseau, MD (1) · Gwenael Layec, PhD (1) · Katherine Beck, Clinical Lecturer (1) · Nikos Evangelou, MD, DPhil (1) · Scott D. Newsome, DO (1)
2023 (1)